Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation

Stéphane Ederhy1, Emanuele Di Angelantonio, Ziad Mallat

  • 1Cardiology Department, Saint-Antoine University and Medical School, Université Pierre et Marie Curie, and INSERM U689, Hôpital Lariboisière, Paris, France.

Insights

Circulating procoagulant microparticles (MPs) are elevated in atrial fibrillation (AF) patients, indicating a hypercoagulable state. This finding may link AF to increased risk of thrombosis and thromboembolism.

Area of Science:

  • Hematology
  • Cardiology
  • Thrombosis Research

Background:

  • Circulating procoagulant microparticles (MPs) are cell fragments with procoagulant properties.
  • Elevated MP levels are observed in severe thrombotic conditions.
  • Atrial fibrillation (AF) is associated with an increased risk of thromboembolism.

Purpose of the Study:

  • To investigate whether circulating procoagulant MP levels are increased in patients with nonvalvular atrial fibrillation (AF).
  • To explore the potential link between elevated MPs and a hypercoagulable state in AF.

Main Methods:

  • A hospital-based case-control study.
  • Measurement of circulating Annexin V-positive MPs in 45 AF patients (without anticoagulant therapy) and 90 age-matched controls.
  • Subgroup analysis of platelet-derived and endothelial-derived MPs.

Main Results:

  • Annexin V-positive MP levels were significantly higher in AF patients compared to both control groups (p<0.001).
  • Platelet-derived and endothelial-derived MPs were higher in AF patients than in controls without cardiovascular risk factors.
  • AF was identified as a strong predictor of elevated Annexin V-positive MP levels (p<.001).

Conclusions:

  • Circulating procoagulant MPs are elevated in persistent and/or permanent AF.
  • Increased MP levels in AF may signify a hypercoagulable state.
  • This hypercoagulability could contribute to the pathogenesis of atrial thrombosis and thromboembolism in AF patients.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...